Molecular and Cellular Oncogenesis

分子和细胞肿瘤发生

• 批准号: 8690263
• 负责人: Dario C Altieri
• 金额: $ 3.77万
• 依托单位: WISTAR INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-03-01 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8690263
• 关键词: Area; Basic Cancer Research; Biological Markers; Biology; Budgets; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Research Project; Collaborations; Direct Costs; Disease; Disease Resistance; Education; Faculty; Foundations; Funding; Gene Expression Regulation; Goals; Growth; Instruction; Interest Group; Investigation; Lead; Left; Maintenance; Malignant Neoplasms; Malignant neoplasm of ovary; Mentors; Mission; Molecular; National Cancer Institute; Neoplasm Metastasis; Pathway interactions; Peer Review; Program Research Project Grants; Publications; Recruitment Activity; Research; Research Personnel; Resource Sharing; Role; Scientist; Signal Transduction; Therapeutic; Work; anticancer research; base; cancer diagnosis; cancer therapy; career development; disease diagnosis; melanoma; member; multidisciplinary; novel; patient oriented; programs; stem cell differentiation; tumor; tumor microenvironment; tumorigenesis

PROJECT SUMMARY (See instructions): The Molecular and Cellular Oncogenesis Program (MCO) is comprised of eleven investigators who work collaboratively in broad areas of cancer biology. Over the last budget period, the MCO Program has undergone an extensive realignment in research focus, thematic areas of collaboration and Program membership. In line with the strategic reorganization ofthe Cancer Center, the MCO Program appointed a new Program Leader (Dr. Murphy), recruited four new investigators at all academic ranks, and received one faculty member (Dr. Janicki) from the Gene Expression and Regulation (GER) Program. Concomitantly, three MCO members transferred to the newly created Program in Tumor Microenvironment and Metastasis (TMM). As a result, the MCO Program is now a more focused and highly collaborative research initiative, bringing together multidisciplinary expertise around three general flagship themes: Mechanisms of growth control (i); Cancer biomarkers and bio-signatures (ii); and Targeted cancer therapeutics (iii). The overarching goal of the Program is to combine a mechanistic understanding of cancer signaling networks with novel molecular approaches to disease diagnosis and treatment, along the continuum of basic, translational and patient-oriented cancer research. Synergy among the scientists is facilitated by a strong programmatic foundation in computational and integrative biology, a broad utilization of Cancer Center Shared Resources, and productive inter-programmatic and inter-institutional collaborations. Over the last budget period, MCO investigators made impressive gains on a broad portfolio of scientific discoveries in line with Program goals. The National Cancer Institute (NCI) funding base of the Program has grown by 27% compared to the last budget period, from $2.05 million in 2008 to $2.79 million in 2013 (direct costs), and the rate of collaborative publications has increased by more than five-fold, from 6.9% in 2008 to 36% in 2013 (total of intra- and inter-programmatic publications), with a total of 187 peer-reviewed cancer-relevant publications. MCO investigators continue to lead large programmatic and disease-relevant collaborations (Program Project grants, SPORE), contribute substantially to the translational mission of the Cancer Center in the Melanoma and Ovarian Cancer Research Continuum Signatures, and actively participate in education, mentoring and career development of faculty and trainees. The MCO Program will continue to build on these strengths during the next budget period, further expanding its unifying role as a multidisciplinary hub for basic and translational cancer research.

项目摘要（请参阅说明）： 分子和细胞肿瘤发生程序（MCO）由11名在癌症生物学广泛领域合作的研究者组成。在上一个预算期内，MCO计划在研究重点，协作和计划成员资格的主题领域进行了广泛的重组。根据癌症中心的战略重组，MCO计划任命了一名新计划负责人（Murphy博士），招募了所有学术级别的四名新调查人员，并从Gene表达和监管（GER）计划中获得了一名教职员工（Janicki）。同时，三名MCO成员转移到新创建的肿瘤微环境和转移（TMM）的计划中。结果，MCO计划现在是一项更加集中和高度协作的研究计划，将围绕三个通用旗舰主题的多学科专业知识汇总在一起：增长控制机制（i）；癌症生物标志物和生物签名（II）；和靶向癌症治疗剂（III）。该计划的总体目的是将对癌症信号网络的机械理解与新型的疾病诊断和治疗方法相结合，沿基本，转化和以患者为导向的癌症研究的连续性结合使用。科学家之间的协同作用是由计算和综合生物学的强大程序基础促进的，癌症中心共享资源的广泛利用以及富有成效的竞争间和机构间合作。在上一个预算期间，MCO调查人员在与计划目标的一致的广泛科学发现方面取得了令人印象深刻的收益。 The National Cancer Institute (NCI) funding base of the Program has grown by 27% compared to the last budget period, from $2.05 million in 2008 to $2.79 million in 2013 (direct costs), and the rate of collaborative publications has increased by more than five-fold, from 6.9% in 2008 to 36% in 2013 (total of intra- and inter-programmatic publications), with a total of 187 peer-reviewed cancer-relevant出版物。 MCO调查人员继续领导大型程序化和与疾病相关的合作（计划项目补助金，孢子），为黑色素瘤和卵巢癌研究中的癌症中心的转化任务做出了重大贡献，并积极参与教育，教师和教练的教育，指导和职业发展。 MCO计划将在下一个预算期间继续基于这些优势，进一步扩大其作为基础和转化癌症研究的多学科枢纽的统一角色。